Innovative Targeted and Immune-Mediated Cancer Therapies
Pipeline
Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients
Science
Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics
News
March 25,
2025
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 13,
2025
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
February 10,
2025
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Events
Tuesday,
December 3RD,
2024
at
9:00 AM
Eastern
Piper Sandler 36th Annual Healthcare Conference
Listen: Webcast
Thursday,
June 20TH,
2024
at
8:30 AM
Eastern
Amezalpat (TPST-1120) Global Randomized Phase 1b/2 Combination Study Update Call
Listen: Webcast
Download: Presentation [pdf]
Wednesday,
October 11TH,
2023
at
8:30 AM
Eastern
TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call
Listen: Webcast
Download: Presentation [pdf]